Consortium strategy

The Pediatric Praziquantel Consortium aims to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in this age group. Our strategy comprises two arms:

The Consortium builds a sustainable partnership by:

  1. Working with credible and experienced partners
  2. Using an R&D operating model that allows new partners to join as needed 
  3. Performing a regular gap analysis to identify the need for additional expertise, resources and/or funding and pro-actively identify future partners or funding opportunities

The Consortium pro-actively promotes dialogue at all stakeholder levels to help ensure project involvement and support through:

  1. Continuous and tailored communication of the rationale and background of the project with key stakeholders.
  2. Regular consultation of pharmaceutical, (non-)clinical, and regulatory experts in the field of pediatric medicine and schistosomiasis.
  3. Early dialogue with relevant health authorities, like ANVISA, WHO PQP, FDA and EMA, to agree on the clinical development plan and achieve registration within the shortest timeframe possible.
  4. Early dialogue with relevant stakeholders to understand their perspective on the orally dispersible praziquantel formulation with the aim to provide preschool-age children and infants in Sub-Saharan Africa and Brazil with fast access to the new formulations. 

Through this multi-stakeholder approach, the Consortium continues to work on the full clinical development program, and on registration and access strategies to ensure that the future product can be made available for those young patients in need.

Learn more about our governance structure here.